Leo Wealth LLC Has $58.49 Million Holdings in Johnson & Johnson $JNJ

Leo Wealth LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 382,885 shares of the company’s stock after acquiring an additional 6,032 shares during the quarter. Johnson & Johnson comprises approximately 4.5% of Leo Wealth LLC’s holdings, making the stock its 3rd largest holding. Leo Wealth LLC’s holdings in Johnson & Johnson were worth $58,486,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Apexium Financial LP boosted its position in shares of Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after acquiring an additional 2,310 shares during the last quarter. Avanza Fonder AB lifted its position in Johnson & Johnson by 2.9% in the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after buying an additional 6,566 shares during the last quarter. Joel Isaacson & Co. LLC lifted its position in Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after buying an additional 2,526 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. lifted its position in Johnson & Johnson by 7.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock worth $12,164,000 after buying an additional 4,816 shares during the last quarter. Finally, Absher Wealth Management LLC lifted its position in Johnson & Johnson by 1.2% in the first quarter. Absher Wealth Management LLC now owns 215,584 shares of the company’s stock worth $35,752,000 after buying an additional 2,469 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $190.66 on Friday. The firm has a market cap of $459.16 billion, a P/E ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $192.10. The stock’s fifty day moving average price is $178.48 and its 200-day moving average price is $163.76.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s payout ratio is 55.61%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. The Goldman Sachs Group raised their price target on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday. HSBC lifted their target price on Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $192.94.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.